Cutilite Cream – Advanced Skin Lightening & Brightening Treatment
Product Highlights:
- Contains Hydroquinone 2% + Tretinoin 0.025% + Mometasone 0.1%
- Clinically proven to reduce dark spots & hyperpigmentation
- Triple-action formula for comprehensive skin correction
- Non-greasy, fast-absorbing cream
- Visible results in 4-6 weeks
- Same Day Delivery (order Mon-Fri before 12:00, with nominal charges)
- FREE Shipping Costs, on orders over ₹999
- 10 days to change your mind and free returns
- Customer Service
Description
Product Description:
Three powerful active ingredients are combined by Cutilite Cream to effectively treat stubborn skin discoloration. This prescription-strength formula is worked by: reducing melanin production (Hydroquinone), accelerating skin renewal (Tretinoin), and reducing inflammation (Mometasone). Ideal for melasma, post-inflammatory hyperpigmentation, and age spots, dramatic results are delivered when regular creams fail. Visible brightening is provided by the carefully balanced formulation while irritation is minimized. Best used under medical supervision for optimal safety and effectiveness.
Best Features:
- Targets multiple causes of pigmentation
- Prevents new dark spot formation
- Gentle exfoliation for even skin tone
- Reduces redness & inflammation
- Dermatologist-recommended
Key Benefits:
- Fades dark spots effectively
- Evens out skin tone
- Reduces acne marks
- Improves skin texture
- Prevents pigment recurrence
How to Use:
- Cleanse and dry face completely
- Apply pea-sized amount at bedtime
- Avoid eye and mouth areas
- Use sunscreen daily during treatment
- Limit use to prescribed duration
Key Ingredients:
- Hydroquinone 2% – Gold-standard skin lightener
- Tretinoin 0.025% – Vitamin A derivative for cell turnover
- Mometasone 0.1% – Potent anti-inflammatory steroid
- Glycolic Acid – Enhances ingredient penetration
Other Info:
- Country of Origin: India
- Manufactured By: Hegde & Hegde Pharmaceuticals
- Marketed By: Hegde & Hegde Pharmaceuticals
Reviews
There are no reviews yet.